Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


20.10.2025

3 BJU Int
1 BMC Cancer
1 Br J Cancer
2 Br J Radiol
1 Cancer
2 Clin Cancer Res
1 Eur Urol
1 Int J Cancer
5 Int J Radiat Oncol Biol Phys
3 Int J Urol
1 J Clin Oncol
1 J Nucl Med
1 Magn Reson Imaging
1 Nat Rev Urol
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Urol Int


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. UEKI H, Uemura M, Chinzei K, Takahashi K, et al
    Developing an artificial intelligence model for phase recognition in robot-assisted radical prostatectomy.
    BJU Int. 2025;136:891-901.
    PubMed         Abstract available

  2. HANDA N, Shore ND, Cooperberg MR, Davicioni E, et al
    Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
    BJU Int. 2025;136:920-929.
    PubMed         Abstract available

  3. CANNOLETTA D, Stabile A, Quarta L, Barletta F, et al
    Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history.
    BJU Int. 2025 Oct 13. doi: 10.1111/bju.70027.
    PubMed         Abstract available


    BMC Cancer

  4. YEBOAH KO, Atawuchugi P, Baah FK, Petershie BE, et al
    The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.
    BMC Cancer. 2025;25:1552.
    PubMed         Abstract available


    Br J Cancer

  5. ZUCKER K, McInerney C, Glaser A, Baxter P, et al
    Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
    Br J Cancer. 2025;133:1137-1144.
    PubMed         Abstract available


    Br J Radiol

  6. KURU OZ D, Yilmazer Zorlu SN, Eskalen Z, Haliloglu N, et al
    Reevaluating prostate imaging-reporting and data system 3 lesions upgraded to 4: the emergence of a new subgroup?
    Br J Radiol. 2025;98:1683-1689.
    PubMed         Abstract available

  7. COOPER S, Chick J, Casey F, Alexander S, et al
    Simulation-free radiotherapy on the MR-linac in prostate cancer.
    Br J Radiol. 2025;98:1591-1595.
    PubMed         Abstract available


    Cancer


  8. Erratum to "Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative".
    Cancer. 2025;131:e70105.
    PubMed        


    Clin Cancer Res

  9. BOUZAKI A, Vasquez Osorio E, Kerns S, van Herk M, et al
    Integration of dose surface maps and genetic data identifies the lower posterior rectum as a key region for toxicity after prostate cancer radiotherapy.
    Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2102.
    PubMed         Abstract available

  10. BRIGHI N, Wetterskog D, Vainauskas O, Orlando F, et al
    Liquid biopsy identifies taxane resistance and clonal selection in castration-resistant prostate cancer.
    Clin Cancer Res. 2025 Oct 13. doi: 10.1158/1078-0432.CCR-25-2121.
    PubMed         Abstract available


    Eur Urol

  11. RIAZ IB, Cheng L, Montironi R
    Histopathology-only Artificial Intelligence for Prostate Cancer: Towards Accessible Risk Stratification.
    Eur Urol. 2025 Oct 10:S0302-2838(25)04722-0. doi: 10.1016/j.eururo.2025.09.4164.
    PubMed        


    Int J Cancer

  12. VLAMING M, Bleiker EMA, Schijven G, Kiemeney LALM, et al
    Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.
    Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70194.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  13. FITZPATRICK KJ, Mikell JK, Roseland ME, Niedbala J, et al
    (177)Lu-PSMA-617 Single-Photon Emission Computed Tomography/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles.
    Int J Radiat Oncol Biol Phys. 2025;123:937-946.
    PubMed         Abstract available

  14. DONG A, Sun X, Chen L, Tsai Y, et al
    KDM3B Regulates Postradiation Fibrotic Responses in Prostate Stroma via N(6)-methyladenosine Modification of LOX.
    Int J Radiat Oncol Biol Phys. 2025;123:1116-1131.
    PubMed         Abstract available

  15. LUKKA HR, Pugh SL, Shipley WU, Major PP, et al
    Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.
    Int J Radiat Oncol Biol Phys. 2025;123:990-999.
    PubMed         Abstract available

  16. SAYAN M, Miric G, Wallner KE, King MT, et al
    Beyond the Beam: Redefining Survivorship in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025;123:1000-1003.
    PubMed        

  17. NEILSEN BK, Huang RR, Valle LF, Proudfoot JA, et al
    Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 29:S0360-3016(25)06298.
    PubMed         Abstract available


    Int J Urol

  18. KAWAHARA T
    Re: Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70259.
    PubMed        

  19. ALANBUKI A
    Editorial Comment: Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70264.
    PubMed        

  20. YAJIMA S, Yoshida S, Fukushima H, Hirakawa A, et al
    Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 12. doi: 10.1111/iju.70256.
    PubMed        


    J Clin Oncol

  21. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    PubMed         Abstract available


    J Nucl Med

  22. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025 Oct 16:jnumed.125.270825. doi: 10.2967/jnumed.125.270825.
    PubMed         Abstract available


    Magn Reson Imaging

  23. CHEN R, Hu G, Zhou B, Gan H, et al
    Combination of clinicopathological and MRI based radiomics features in predicting homologous recombination repair genes mutations in prostate cancer.
    Magn Reson Imaging. 2025;124:110534.
    PubMed         Abstract available


    Nat Rev Urol

  24. RATNER D, Vassy JL
    Clinical translation of polygenic scores for prostate cancer screening.
    Nat Rev Urol. 2025 Oct 13. doi: 10.1038/s41585-025-01095.
    PubMed         Abstract available


    PLoS One

  25. LI Y, Gillanders D, Finucane A
    Experience of uncertainty in prostate cancer: A qualitative study.
    PLoS One. 2025;20:e0334180.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  26. XIE J, Shen K, Liang W, Kuang Z, et al
    Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival.
    Proc Natl Acad Sci U S A. 2025;122:e2509222122.
    PubMed         Abstract available


    Urol Int

  27. RISCH J, Hugelmann K, Buck L, von Knobloch HC, et al
    Readability of Prostate Cancer Patient Education Materials: A Comprehensive Assessment Using Readability Metrics.
    Urol Int. 2025 Oct 9:1-15. doi: 10.1159/000548884.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.